
Sign up to save your podcasts
Or


In this episode, we will build up on our previous Weight loss Pharmacotherapy Episode, episode #13 to discuss updates in guidelines, prevention of obesity from comorbidity standpoint, and new treatment agents for weight-loss with a particular focus on Contrave (naltrexone/bupropion), Saxenda (liraglutide), and Wegovy (semaglutide).
By Sean P. Kane, PharmD; Khyati Patel, PharmD4.9
646646 ratings
In this episode, we will build up on our previous Weight loss Pharmacotherapy Episode, episode #13 to discuss updates in guidelines, prevention of obesity from comorbidity standpoint, and new treatment agents for weight-loss with a particular focus on Contrave (naltrexone/bupropion), Saxenda (liraglutide), and Wegovy (semaglutide).

43,529 Listeners

706 Listeners

500 Listeners

265 Listeners

3,379 Listeners

56,821 Listeners

1,146 Listeners

16,979 Listeners

402 Listeners

730 Listeners

296 Listeners

197 Listeners

515 Listeners

117 Listeners

152 Listeners